CALGARY, AB--(Marketwired - February 02, 2015) - Hemostemix Inc. (the “Corporation”) (TSX VENTURE: HEM) announced today the appointment of Dr. Hardean E. Achneck, MD, as vice president of clinical research and operations.
“Hardean brings to Hemostemix a rare combination of scientific expertise and clinical experience,” said Dr. Elmar Burchardt, President and CEO. “His pioneering interdisciplinary research provides a strong foundation for leading our clinical trials and developing clinical trial partnerships.”
Prior to joining the Hemostemix management team, Dr. Achneck held assistant professorships in pathology and surgery at Duke University School of Medicine and in cardiovascular and metabolic disorders at Duke-National University of Singapore Graduate Medical School (Duke-NUS). At these institutions, he served as principal investigator on preclinical and clinical research studies in cardiovascular medicine and was responsible for identifying clinical research opportunities for Duke University Medical Center. He earned an MD degree from Yale University School of Medicine.
Dr. Achneck’s research and development experience includes cell therapies as well as medical combination devices that use endothelial progenitor cells (EPCs) derived from a patient’s blood. He invented a rapid point-of-care cell-seeding technology and authored more than 20 peer-reviewed publications in the field of blood-derived cell therapies.
“Hemostemix presents a unique opportunity to leverage my cell-therapy experience in an entrepreneurial setting,” said Dr. Achneck. “I look forward to advancing the clinical trials, science, and operations in collaboration with our scientific team in Israel.”
About Hemostemix
Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. Hemostemix Inc. is traded on the Toronto Stock Exchange Venture under the trading symbol HEM. For more information, visit hemostemix.com or email office@hemostemix.com.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Qualifying Transaction and associated transactions and has neither approved nor disapproved of the contents of this press release.
For further information, please contact:
Hemostemix Inc.
Dr. Elmar Burchardt
President and CEO
Phone: (617) 500-8401
C.W. (Bill) Baker
Chairman of the Board
Phone: (403) 818-7672
Help employers find you! Check out all the jobs and post your resume.
